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10Abstract
The elevated activity of fatty acid synthase has been reported in a number of cancer
types. Inhibition of this enzyme has been demonstrated to induce cancer cell death
and reduce tumor growth. In addition, the fatty acid synthase inhibitor drug C75
has been reported to synergistically enhance the cancer‐killing ability of ionizing
radiation. However, clinical use of C75 has been limited due to its producing weight
loss, believed to be caused by alterations in the activity of carnitine
palmitoyltransferase‐1. C75 is administered in the form of a racemic mixture of
(−) and (+) enantiomers that may differ in their regulation of fatty acid synthase
and carnitine palmitoyltransferase‐1. Therefore, we assessed the relative cancer‐
killing potency of different enantiomeric forms of C75 in prostate cancer cells. These
results suggest that (−)‐C75 is the more cytotoxic enantiomer and has greater
radiosensitizing capacity than (+)‐C75. These observations will stimulate the devel-
opment of fatty acid synthase inhibitors that are selective for cancer cells and
enhance the tumor‐killing activity of ionizing radiation, while minimizing weight
loss in cancer patients.
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Fatty acid synthase (FASN) is the enzyme responsible for
endogenous synthesis of saturated long‐chain fatty acids from
the precursors acetyl‐CoA and malonyl‐CoA. Many common
human cancers, including carcinoma of the prostate and
breast, express high levels of FASN compared with normal
human tissues.1–3 This elevated expression is associated with
protection against apoptosis, increased metastasis, and poor
prognosis. Inhibitors of FASN decrease prostate cancer cell
proliferation, increase apoptosis, and decrease tumor growth
in experimental models. The natural fungal product cerulenin
is an inhibitor of FASN and a US Food and DrugCreative Commons Attribution‐NonC
t used for commercial purposes.
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eriodicals, Inc.
wileyonlinelibrary.com/journAdministration (FDA)‐approved antiobesity drug. Synthetic
derivatives such as the competitive irreversible FASN inhib-
itor C75 are more chemically stable.
Inhibition of FASN by C75 induced apoptosis in cancer
cells. This was probably caused by elevated levels of the
FASN substrate malonyl‐CoA.4 Malonyl‐CoA also inhibits
carnitine palmitoyltransferase (CPT‐1), the rate‐limiting
enzyme of fatty acid oxidation, preventing the oxidation of
newly synthesized fatty acids.5 CPT‐1 stimulation by C75,
however, does not appear to play a role in the cytotoxic
response.5
We have previously demonstrated that C75 was cytotoxic
to prostate cancer cell lines (PC3 and LNCaP), decreasedommercial License, which permits use, distribution and reproduction in any medium,
ublication.]
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ticellular spheroids composed of LNCaP cells.6 Crucially,
C75 enhanced the clonogenic kill and spheroid growth delay
induced by experimental radiotherapy in a synergistic manner
characteristic of a radiosensitizer.
Although C75 exhibits selective killing of cancer cells, its
side effects of anorexia and weight loss have limited its
potential for the treatment of cancer patients. C75‐induced
modulation of CPT‐1 appears to be responsible for its capac-
ity to reduce weight. However, the mechanism of action is
unresolved. C75 directly activates CPT‐1, leading to
increased fatty acid β‐oxidation with consequent weight
loss.7,8 Conversely, experiments in vitro and in rodent models
demonstrated that C75 is converted to C75‐CoA.9,10 Accu-
mulation of C75‐CoA and malonyl‐CoA, caused by reduced
FASN activity, act as signals of nutrient abundance to
hypothalamic neurons, inhibiting CPT‐1 and mediating the
suppression of food intake and further contributing to weight
loss.11 This has led to the evaluation of drugs that inhibit
FASN but do not affect CPT‐1 activity.12,13
Mims et al.14 recently demonstrated that inhibition of
FASN sensitized cancer cells to experimental radiation
therapy. However, that study used orlistat, which is poorly
soluble and has an extremely low oral bioavailability,15 thus
limiting its clinical application. Radiosensitization of cancer
cells was also achievable using C75.6 However, it is possible
that the racemic mixture of C75 may modulate the activity of
CPT‐1 activity, which is responsible for its undesirable
effects on body weight and appetite in patients with cancer.11
Here we evaluated the radiosensitizing activity of enantio-
mers of C75 in comparison with the commonly used racemic
mixture of C75.FIGURE 1 Structure of the enantiomers of C75.
FIGURE 2 Cytotoxicity of different stereoisomers of C75. MTT assay of A, PC3
commercial sources (Sigma‐Aldrich and Santa Cruz Biotechnology), or (−) and2 | MATERIALS AND METHODS
Human prostate cancer cell lines PC3 and LNCaP were
obtained from the American Type Culture Collection
(Manassas, VA) and were used in this study for less than
6 months after resuscitation. Cell lines were maintained as
previously described.6 Racemic mixtures of C75 were pur-
chased from Sigma‐Aldrich (Dorset, UK) and Santa Cruz
Biotechnology (Santa Cruz, CA). Enantiomers of C75 [(−)‐
trans‐C75 and (+)‐trans‐C75] were purchased from Santa
Cruz Biotechnology. The structure of the enantiomers of
C75 is shown in Figure 1. A methyl tetrazolium (MTT) cyto-
toxicity assay was performed on cell lines in 96‐well plates
after administration of drugs for 24 h. For clonogenic assay,
PC3 cells in exponential growth phase were treated with
drugs alone or in simultaneous combination with radiation
using an X‐Strahl RS225 X‐ray irradiator at a dose rate of
1.6 Gy per min. After 24 h treatment, cells were seeded for
clonogenic survival assay. Cells were incubated at 37°C in
5% CO2 for 10 days. Colonies were fixed in methanol,
stained with crystal violet solution, and colonies of at least
50 cells were counted. Data are presented as means ±
standard error of the mean (SEM) of three separate experi-
ments. Statistical significance was determined usingand B, LNCaP cells in response to racemic mixtures of C75 (+/−) from two
(+) enantiomers of C75 from Santa Cruz Biotechnology.
FIGURE 3 Clonogenic survival of PC3 prostate cancer cells in response to
racemic mixtures and enantiomers of C75.
FIGURE 4 Enhancement of the clonogenic killing activity of x‐radiation by C75 administered in the form of a racemic mixture (+/−) or (−) and (+)
enantiomers (Santa Cruz Biotechnology). PC3 cells were treated simultaneously with x‐radiation (2 Gy) and A, 10 μM or B, 25 μM C75. *P < 0.05,
**P < 0.01 compared with x‐radiation alone.
12 RAE ET AL.Student's t‐test. P < 0.05 was considered statistically signifi-
cant and <0.01 highly significant.3 | RESULTS AND DISCUSSION
The potency of C75, obtained from Sigma‐Aldrich and used
in previous studies, was compared with a racemic mixture
and enantiomers purchased from Santa Cruz Biotechnology.
The two racemic mixtures had almost identical cytotoxic
potency in both cell lines (Figure 2). However, the (−) enan-
tiomer was more potent than the racemic mixture, whereas
the (+) enantiomer had less potency than the racemic mixture
in both cell lines. This is in agreement with the antitumor
effect of C75 previously described by Makowski et al.11 in
breast and ovarian cancer cell lines, wherein the (+) enantio-
mer of C75 was less potent than the racemic mixture or the
(−) enantiomer. Similar to the cytotoxicity assays, in
clonogenic assays of PC3 cells the racemic mixtures had near
identical activity, which was less than the (−) enantiomer and
more than the (+) enantiomer (Figure 3). In clonogenic
assays, the 50% clonogenic kill (IC50) values were
37.01 ± 1.45 and 37.81 ± 1.23 μM for Sigma‐Aldrich and
Santa Cruz C75, respectively. The (−) enantiomer of C75
had significantly greater clonogenic killing potency (IC50
28.08 ± 0.66 μM) than the racemic mixture, whereas the
(+) enantiomer of C75 had substantially less effect, reflected
in an IC50 value of 51.36 ± 7.67 μM.
For the first time, the radiosensitizing activity of C75
enantiomers was also evaluated. Greater than additive
enhancement of radiation‐induced clonogenic kill was
observed with the racemic mixture of C75 or the (−) enantio-
mer when administered at 25 μM (Figure 4). In contrast,
(+)‐C75 did not induce a significant enhancement of
radiation‐induced clonogenic kill. Crucially, the
radiosensitizing activity of (−)‐C75 was evident even when
administered at 10 μM—a concentration that does not induce
significant clonogenic cell kill (Figure 2a).
It has previously been reported that, although C75 had a
minimal effect on CPT‐1 activity, (+)‐C75‐CoA inhibitedCPT‐1 to a significantly greater extent than either racemic
C75‐CoA or (−)‐C75‐CoA.11 Furthermore, when injected
into rats the anorectic effect of C75 was largely attributed to
the presence of (+)‐C75.11 These findings, combined with
the observations that (−)‐C75 was able to inhibit FASN
activity and was cytotoxic to cancer cell lines, suggested that
(−)‐C75 is likely to display the beneficial antitumor effects in
the absence of significant side effects associated with the
racemic C75. Therefore, we assessed the radiopotentiation
of the stereoisomers of C75 in vitro and observed that the
radiosensitizing activity was a property only of the (−)‐C75
enantiomer. Importantly, the clonogenic killing potency of
(−)‐C75 was greater than either racemic C75 or (+)‐C75. It
is expected that clinical application of the (−) enantiomer of
C75 will improve the treatment of metastatic prostatic carci-
noma without inducing adverse anorexia. This combination
of (−)‐C75 with radiotherapy is also likely to be effective in
other tumor types that overexpress fatty acid synthase.4 | CONCLUSION
We demonstrate here that the antitumor potential and
radiosensitizing activity of C75 is due to the (−)‐C75
enantiomer. It is expected that therapeutic use of this enantio-
mer will reduce the previously limiting clinical effect of
weight loss in cancer patients.
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